武文娣,李克莉,郑景山,刘大卫,许涤沙,杨宏,曹雷,曹玲生,袁平,王华庆,李黎

• 1:中国疾病预防控制中心免疫规划中心

摘要(Abstract)：

目的分析全国(未包括香港、澳门特别行政区和台湾地区,下同)2011年疑似预防接种异常反应(Adverse Events Following Immunization,AEFI)的发生特征,评价AEFI信息管理系统运转情况及预防接种安全性。方法通过全国AEFI信息管理系统,收集截至2012年12月24日报告的2011年发生的AEFI个案数据,用描述流行病学方法进行分析。结果全国2011年AEFI信息管理系统共收到76205例个案,比2010年增加了36.08%。全国共有2671个县(区、市、旗,下同)有数据报告,占总县数的86.27%;48h内报告率为97.17%,48h内调查率为98.91%。AEFI报告数男、女性别比为1.42:1,≤1岁占73.17%。根据中国2011年免疫规划信息管理系统中疫苗接种剂次估算,AEFI总发生率为15.56/10万剂,严重AEFI估算发生率为0.18/10万剂,预防接种异常反应估算发生率为1.27/10万剂。不良反应中,一般反应以发热、红肿、硬结为主,预防接种异常反应以过敏性皮疹、卡介苗淋巴结炎为主。不良反应主要集中在接种后≤1d。在所有AEFI中,治愈和好转占98.98%,死亡105例,其中预防接种异常反应17例。结论全国AEFI监测的敏感性有较大提高,但西部各省(自治区、直辖市)仍是薄弱地区;AEFI常发生在小年龄儿童和接种后≤1d;国家免疫规划疫苗预防接种异常反应报告发生率均在预期发生范围内。

关键词(KeyWords)： 疑似预防接种异常反应;监测

Abstract:

Keywords:

基金项目(Foundation):

作者(Author): 武文娣,李克莉,郑景山,刘大卫,许涤沙,杨宏,曹雷,曹玲生,袁平,王华庆,李黎

参考文献(References)：

• [1]卫生部,国家食品药品监督管理局.全国疑似预防接种异常反应监测方案[S].2010-06-03.Ministry of Health,State Food and Drug Administration of the People’s Republic of China.National Guideline for the Surveillance of Adverse Events Following Immunization[S].2010-06-03.
• [2]常利民,刘大卫,王华庆.国内外预防接种异常反应监测报告和诊断标准的研究现状[J].中国疫苗和免疫,2012,18(5):465-468.CHANG Li-min,LIU Da-wei,WANG Hua-qing.The Research Status of Diagnosis Standsrd and Surveillance and Reporting of Adverse Event Following Immunization in China and Abroad[J].Chinese Journal of Vaccine and Immunization,2012,18(5):465-468.
• [3]刘大卫,郭飚,曹玲生,等.全国2005～2006年疑似预防接种异常反应监测分析[J].中国计划免疫,2007,13(6):505-513.LIU Da-wei,GUO Biao,CAO Ling-sheng,et al.Study on the Surveillance of Adverse Events Following Immunization in China,2005-2006[J].Chinese Journal of Vaccines and Immunization,2007,13(6):505-513.
• [4]武文娣,刘大卫,吴冰冰,等.全国2007～2008年疑似预防接种异常反应监测分析[J].中国疫苗和免疫,2009,15(6):481-490.WU Wen-di,LIU Da-wei,WU Bing-bing,et al.Analysis on the Surveillance of Adverse Events Following Immunization in China,2007-2008[J].Chinese Journal of Vaccines and Immunization,2009,15(6):481-490.
• [5]武文娣,刘大卫,李克莉,等.全国2009年疑似预防接种异常反应监测分析[J].中国疫苗和免疫,2011,17(2):99-108.WU Wen-di,LIU Da-wei,LI Ke-li,et al.Analysis on Adverse Events Following Immunization Surveillance in China,2009[J].Chinese Journal of Vaccines and Immunization,2011,17(2):99-108.
• [6]武文娣,刘大卫,李克莉,等.中国2010年疑似预防接种异常反应监测数据分析[J].中国疫苗和免疫,2012,18(5):385-397.WU Wen-di,LIU Da-wei,LI Ke-li,et al.Analysis on Adverse Events Following Immunization Surveillance in China,2010[J].Chinese Journal of Vaccines and Immunization,2012,18(5):385-397.
• [7]Deepika M,Jane C,Peter B,et al.Annual Report:Surveillance of Adverse Events Following Immunization in Australia,2010[J].CDI,2011,35(4):263-280.
• [8]刘大卫,郭飚,曹玲生,等.吸附无细胞和全细胞百日咳-白喉-破伤风联合疫苗上市后预防接种安全性的比较分析[J].中国疫苗和免疫,2008,14(2):97-102.LIU Da-wei,GUO Biao,CAO Ling-sheng,et al.Comparative Study on Post-Marketing Immunization Safety of Absorbed Diphtheria,Tetanus and Acellular Pertusis Combined Vaccine,and Absorbed Diphtheria,Tetanus and Whole-cell Pertusis Combined Vaccine in China[J].Chinese Journal of Vaccines and Immunization,2008,14(2):97-102.
• [9]李克莉,刘大卫,武文娣,等.2009～2010年全国卡介苗疑似预防接种异常反应监测分析[J].中国疫苗和免疫,2012,18(3):252-260.LI Ke-li,LIU Da-wei,WU Wen-di,et al.Analysis on Surveillance of Adverse Events Following Immunization for Bacille Calmette-Guéri Vaccine in China,2009-2010[J].Chinese Journal of Vaccines and Immunization,2012,18(3):252-260.
• [10]WHO&WPRO.Immunization safety surveillance:guidelines for managers of immunization programmes on reporting and investigating adverse events following immunization[S].Manila,Philippines,1999.
• [11]武文娣,刘大卫,李克莉,等.中国2010年含麻疹成分疫苗强化免疫活动疑似预防接种异常反应监测分析[J].中国疫苗和免疫,2012,18(5):402-407.WU Wen-di,LIU Da-wei,LI Ke-li,et al.Analysis on the Adverse Events Following Immunization after Supplementary Immunization Activity of Measles-contained Vaccine in China,2010[J].Chinese Journal of Vaccines and Immunization,2012,18(3):402-407.
• [12]Pless RP,Bentsi-Enchill AD,Duclos P,et al.Monitoring Vaccine Safety during Measles Mass Immunization Campaigns:Clinical and Programmatic Issues[J].The Journal of Infectious Diseases,2003,187(Suppl1):S291-298.
• [13]岳晨妍,李克莉,郭飚,等.中国5个县级监测点疑似预防接种异常反应监测分析[J].中国疫苗和免疫,2012,18(3):246-251.YUE Chen-yan,LI Ke-li,GUO Biao,et al.Analysis on Pilot Surveillance Counties of Adverse Events Following Immunization in China[J].Chinese Journal of Vaccines and Immunization,2012,18(3):246-251.
• [14]王亚敏,刘大卫,李克莉,等.全国2009-2010年格林-巴利综合征疑似预防接种异常反应监测分析[J].中国疫苗和免疫,2012,18(5):408-412.WANG Ya-min,LIU Da-wei,LI Ke-li,et al.Surveillance of Guillain-Barre Sydrome as Adverse Events Following Immunization in China[J].Chinese Journal of Vaccines and Immunization,2012,18(3):408-412.
• [15]Haber P,Sejvar J,Mikaeloft Y,et al.Vaccines and Guillain-Barre Syndrome[J].Drug Safety,2009,32(4):309-323.
• [16]李克莉,刘大卫,武文娣,等.2007～2009年中国六个市血小板减少性紫癜住院病例发生情况分析[J].中国疫苗和免疫,2012,18(2):139-143.LI Ke-li,LIU Da-wei,WU Wen-di,et al.Study on Incidence of Hospitalized Thrombocytopenic Purpura Cases in6Cities in China,2007-2009[J].Chinese Journal of Vaccines and Immunization,2012,18(2):139-143.
• [17]Dipacla JA,Buchanan GR.Immune Thrombocy topenic Purpura[J].Pediatr Clin North America,2002,49(5):911-928.
• [18]Jens UR,Michael SG,Jose-Maria B,et al.Anaphylaxis:Case definition and guidelines for data collection,analysis,and presentation of immunization safety data[J].Vaccine,2007,25(31):5675-5684.
• [19]曹雷,王华庆,郑景山,等.中国扩大国家免疫规划疫苗接种率调查分析[J].中国疫苗和免疫,2012,18(5):419-424.CAO Lei,WANG Hua-qing,ZHENG Jing-shan,et al.National Immunization Coverage Survey in China after Integrated more Vaccines into EPI Since2008[J].Chinese Journal of Vaccines and Immunization,2012,18(3):419-424.
• [20]常利民,刘大卫,李克莉,等.全国2008～2010年接种疫苗后过敏性休克监测结果分析[J].中国疫苗和免疫,2012,18(5):398-401.CHANG Li-min,LIU Da-wei,LI Ke-li,et al.Analysis of Anaphylactic Shock Monitoring Data Following Vaccination in2008-2010[J].Chinese Journal of Vaccines and Immunization,2012,18(5):398-401.